The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses

Nature Immunology

Volumn 5, Issue 10, 2004, Pages 1052-1060

  Boone, David L ^a   Turer, Emre E ^a   Lee, Eric G ^a   Ahmad, Regina Celeste ^a   Wheeler, Matthew T ^b   Tsui, Colleen ^c   Hurley, Paula ^a   Chien, Marcia ^a   Chai, Sophia ^a   Hitotsumatsu, Osamu ^a   McNally, Elizabeth ^b   Pickart, Cecile ^c   Ma, Averil ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOPLASM PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN PROTEIN LIGASE; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; NUCLEAR PROTEIN; PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UBIQUITIN;

ANIMAL CELL; ARTICLE; BIOCHEMISTRY; GENE EXPRESSION; IMMUNOCOMPETENT CELL; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEPTIC SHOCK; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPOLYSACCHARIDES; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NF-KAPPA B; NUCLEAR PROTEINS; PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SHOCK, SEPTIC; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN;

EID: 5444223519     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/ni1110     Document Type: Article

References (41)

1. Takeda, K., Kaisho, T. & Akira, S. Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
2. Janeway, C.A., Jr. & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
3. Akira, S., Takeda, K. & Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2, 675-680 (2001).
4. Barton, G.M. & Medzhitov, R. Toll-like receptor signaling pathways. Science 300, 1524-1525 (2003).
5. Akira, S. Toll-like receptor signaling. J. Biol. Chem. 278, 38105-38108 (2003).
6. Kobayashi, K. et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110, 191-202 (2002).
7. Kinjyo, I. et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 17, 583-591 (2002).
8. Nakagawa, R. et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 17, 677-687 (2002).
9. Zhang, G. & Ghosh, S. Negative regulation of Toll-like receptor-mediated signaling by Tollip. J. Biol. Chem. 277, 7059-7065 (2002).
10. Wald, D. et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. 4, 920-927 (2003).
11. Brint, E. et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5, 373-379 (2004).
12. Chuang, T.-H. & Ulevitch, R. Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat. Immunol. 5, 495-502 (2004).
13. Opipari, A.W., Jr., Boguski, M.S. & Dixit, V.M. The A20 cDNA induced by tumor necrosis factor α encodes a novel type of zinc finger protein. J. Biol. Chem. 265, 14705-14708 (1990).
14. Krikos, A., Laherty, C.D. & Dixit, V.M. Transcriptional activation of the tumor necrosis factor α-inducible zinc finger protein, A20, is mediated by κB elements. J. Biol. Chem. 267, 17971-17976 (1992).
15. Lee, E.G. et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350-2354 (2000).
16. Heyninck, K. & Beyaert, R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-κB activation at the level of TRAF6. FEBS Lett. 442, 147-150 (1999).
17. Cooper, J.T. et al. A20 blocks endothelial cell activation through a NF-κB-dependent mechanism. J. Biol. Chem. 271, 18068-18073 (1996).
18. Nau, G.J. et al. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. USA 99, 1503-1508 (2002).
19. Nomura, F. et al. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J. Immunol. 164, 3476-3479 (2000).
20. Makarova, K.S., Aravind, L. & Koonin, E.V. A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae. Trends Biochem. Sci. 25, 50-52 (2000).
21. Evans, P.C. et al. A novel type of deubiquitinating enzyme. J. Biol. Chem. 278, 23180-23186 (2003).
22. Borodovsky, A. et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9, 1149-1159 (2002).
23. Balakirev, M.Y., Tcherniuk, S.O., Jaquinod, M. & Chroboczek, J. Otubains: a new family of cysteine proteases in the ubiquitin pathway. EMBO Rep. 4, 517-522 (2003).
24. Weissman, A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell. Biol. 2, 169-178 (2001).
25. Lomaga, M.A. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024 (1999).
26. Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346-351 (2001).
27. Deng, L. et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361 (2000).
28. Baud, V. et al. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain. Genes Dev. 13, 1297-1308 (1999).
29. Ohashi, K., Burkart, V., Flohe, S. & Kolb, H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the Toll-like receptor-4 complex. J. Immunol. 164, 558-561 (2000).
30. Okamura, Y. et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 276, 10229-10233 (2001).
31. Evans, P.C. et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem. J. 378, 727-734 (2004).
32. Beyaert, R, Heyninck, K & VanHuffel, S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-κB-dependent gene expression and apoptosis. Biochem. Pharmacol. 60, 1143-1151 (2000).
33. Song, H.Y., Rothe, M. & Goeddel, D.V. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-κB activation. Proc. Natl. Acad. Sci. USA 93, 6721-6725 (1996).
34. Brummelkamp, T.R., Nijman, S.M., Dirac, A.M. & Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424, 797-801 (2003).
35. Kovalenko, A. et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424, 801-805 (2003).
36. Trompouki, E. et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424, 793-796 (2003).
37. Bignell, G.R. et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25, 160-165 (2000).
38. Wertz, I.E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694-699 (2004).
39. + T cells is dispensable for T cell memory. Proc. Natl. Acad. Sci. USA 100, 4724-4729 (2003).
40. Chutkow, W.A. et al. Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels. J. Clin. Inv. 110, 203W. A. 208 (2002).
41. Hofmann, R.M. & Pickart, C.M. In vitro assembly and recognition of Lys-63 poly-ubiquitin chains. J. Biol. Chem. 276, 27936-27943 (2001).